COULD being the key word there. Your opinion as to the company going up is just that an opinion.
I'll reasses SPL after May's webinar. Looking for them to explain strategy, funding, licence deals, commercial contracts and operating costs. I also want to hear more on the FDA decision to not pursue the NDA for vivagel (having participated in CRs).
With all that's gone before in research, development, proof of concept and taking 2 drugs to market with limited success, to now have to go through the process again, is not where a 20 year plus BIO company should be IMO.
SPL Price at posting:
14.0¢ Sentiment: None Disclosure: Not Held
